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Background
Cardiac imaging in obese adults poses significant technical
challenges, yet the prognostic value of diffuse myocardial
fibrosis in obese adults quantified with cardiovascular
magnetic resonance (CMR) extracellular volume fraction
(ECV) measures is unknown. This issue is important
because obesity increases the risks of death and hospitali-
zation for heart failure (HHF). Myocardial fibrosis mea-
sured in obese adults with ECV may indicate vulnerability
to death and HHF.
Methods
We enrolled 480 consecutive obese patients with a BMI
>30 referred for cardiovascular magnetic resonance
(CMR) without amyloidosis, stress cardiomyopathy, or
hypertrophic cardiomyopathy. We quantified myocardial
fibrosis with CMR ECV measures in noninfarcted myo-
cardium. Patient data, BMI, hematocrit, were collected on
the day of CMR, and we tracked outcomes prospectively.
Results
Median BMI was 35 (IQR 32-41), and median ECV was
27.7% (IQR 25.6%-30.9%, range). BMI and ECV were
not related (p=0.90). Over a median 1.5 years (IQR 0.9-
2.5yrs), 27 HHF events and 28 deaths occurred after
CMR in 50 individuals. Adjusting for age, gender, renal
function, myocardial infarction size, ejection fraction,
hospitalization status, and heart failure stage, ECV in
obese adults was associated with HHF (HR1.92 95%CI
1.40-2.65 for every 5% increase in ECV (ECV range:
16.6-45.8), death (HR 2.50 95%CI 1.59-3.95) or both
(HR1.97 95%CI 1.44-2.70). ECV improved the classifica-
tion of obese adults at risk and improved model discri-
mination for the composite outcome: e.g., HHF or death
[continuous net reclassification improvement (NRI)
0.429, 95%CI 0.063-0.758; p=0.02; integrated discrimina-
tion improvement (IDI) 0.069, 95% CI 0.016-0.132;
p=0.02].
Conclusions
Despite the challenges of cardiac imaging in obese
adults, diffuse myocardial fibrosis quantified by ECV is
associated with HHF, death, or both. Myocardial fibrosis
may represent a principal marker of cardiac vulnerability
that improves risk stratification even in the setting of
obesity. Since myocardial fibrosis can be reversible,
myocardial fibrosis and the fibroblast that regulates it
may be attractive therapeutic targets in obese patients.
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Figure 1
Table 1 In multivariable models, EC in noninfarcted myocardium in obese patients remained associated with the
combined endpoint of HHF/death. The addition of ECV improved the classification of individuals at risk (new
reclassification improvement, NRI) and the discrimination of the model (integrated discrimination improvement, IDI).
Multivariable Cox regression model Hazard Ratio for every
5% increase in ECV (95%
CI; p value)
Category free
NRI (95% CI; p
value)
Categorical NRI 0,.05,
0.10 risk categories
(95%CI); p value)
IDI (95%
CI; p
value)
Modeling composite of HHF or death,
stratified by heart failure stage and hospitalization
status, adjusted for EF, age, glomerular filtration rate,
myocardial infarction size, and gender
1.97
(1.44-2.70; p<0.001)
0.43
(0.06-0.76;
p=0.02)
0.04
(0.005-0.079; p=0.02)
0.069
(0.016-
0.132;
p=0.02)
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